SCS during pregnancy: 3 Crucial Risks

Understanding the Challenges of Spinal Cord Stimulation in Pregnancy

SCS during pregnancy is a relative contraindication according to most manufacturers, primarily due to limited safety data on its effects on a developing fetus. However, many women with existing devices face this situation, and emerging evidence suggests outcomes are often favorable. For those managing severe chronic pain from conditions like Complex Regional Pain Syndrome (CRPS), turning off an SCS device can mean returning to debilitating pain, which carries its own risks during pregnancy.

Quick Safety Summary for SCS During Pregnancy:

• Recommendation: Most manufacturers advise turning the device off due to insufficient safety data.
• Reality: 92% of patients in documented cases had their SCS implanted before pregnancy.
• Pain Relief: 84% of pregnant women with SCS achieved >50% pain reduction.
• Maternal Health: 100% of mothers remained healthy.
• Neonatal Outcomes: 88% of newborns were healthy, with 94% having no postnatal complications.
• Critical Factor: A multidisciplinary care team is essential for optimal outcomes.
• Main Risks: Theoretical concerns include electromagnetic field exposure, lead migration, and limited anesthesia options during delivery.

This is not a simple yes-or-no question. It requires a careful balance between the known risks of uncontrolled pain and the theoretical risks of continuing SCS therapy. As a specialist in neuromodulation and chronic pain, I have seen how critical individualized, evidence-based decision-making is for these challenging cases. This article will unpack the evidence to help you steer this complex topic.

Understanding Spinal Cord Stimulation for Chronic Pain

Spinal Cord Stimulation (SCS) is a form of neuromodulation that has transformed chronic pain management. It works on principles like the “gate control theory of pain,” using mild electrical pulses to interrupt or mask pain signals before they reach the brain. The system consists of a small implanted pulse generator (IPG) and thin wires called leads, which are placed in the epidural space near the spinal cord. This Electrical Stimulation Therapy has significantly improved quality of life for many who had exhausted other options.

How SCS Manages Pain and Its Common Indications

SCS is most successful for neuropathic pain – pain caused by nerve damage. It is not a first-line treatment but is reserved for chronic conditions that haven’t responded to conservative approaches. The electrical impulses target the spinal cord’s dorsal column, interrupting pain signal transmission.

• Traditional SCS produced a tingling sensation (paresthesia) to mask the pain.
• Modern high-frequency SCS (HF-SCS) can provide paresthesia-free therapy, a game-changer for patients who found the tingling uncomfortable.
• Patient-controlled programming allows users to adjust stimulation levels, optimizing pain relief and improving quality of life.

Key indications for SCS include:

• Failed Back Surgery Syndrome (FBSS): Persistent pain after spinal surgery. In studies on SCS during pregnancy, FBSS accounted for 24% of patients.
• Complex Regional Pain Syndrome (CRPS): A severe chronic pain condition, often in a limb. CRPS was the most frequent reason for SCS use in pregnant patients, at 72% of cases.
• Other Conditions: Spinal Cord Stimulation SCS for Diabetic Neuropathy and other forms of intractable limb or refractory pain.

Understanding What is SCS Therapy? is vital, as many women with these conditions already have an SCS implanted before becoming pregnant, shifting the question from “Should I get SCS?” to “Should I continue using it?” This is a central theme within A Comprehensive Algorithm for Management of Neuropathic Pain.

The Official Stance and Potential Risks of SCS During Pregnancy

Official guidelines from manufacturers and regulatory bodies like the FDA are cautious, generally considering pregnancy a relative contraindication for SCS use. This stance reflects the lack of large-scale studies on how SCS affects pregnant women and fetal development. Most manufacturers suggest deactivating the device once pregnancy is confirmed.

However, real-world data from a review in Spinal Cord Stimulation in Pregnant Patients – A Review shows 92% of patients had their SCS implanted before pregnancy. These women face a dilemma: turn off the device and endure severe pain, or continue therapy with uncertain risks? This gap highlights the need for individualized care.

Key Concerns and Potential Risks

The cautious approach stems from several theoretical concerns and potential risks for both mother and fetus:

• Electromagnetic Field Exposure: SCS devices generate electromagnetic fields. While the specific effects on a fetus are unknown, some research has suggested a possible link between high magnetic field exposure and miscarriage risk, leading to the precautionary recommendation to deactivate the device.
• Unknown Effects on Fetal Development: Without clinical trials on pregnant women (due to ethical constraints), the long-term effects of chronic electrical stimulation on a baby’s developing organs and nervous system remain unknown. This is a significant knowledge gap.
• Lead Migration and Device Malfunction: Pregnancy causes significant physiological changes (weight gain, postural shifts) that can put mechanical stress on the SCS leads. This could cause lead migration (seen in 3% of cases) or breakage, leading to loss of pain relief or unintended stimulation.
• Challenges with Imaging and Delivery: While many modern SCS devices are MRI-conditional, precautions are still needed. Anesthesia options during labor, particularly epidurals, may be limited due to the risk of damaging the leads.
• Pain Management Limitations: Deactivating the SCS may necessitate using pain medications, many of which have known risks during pregnancy. You can read more about these Challenges in chronic pain management during pregnancy.
• Pregnancy Outcomes: In reviewed cases, the miscarriage rate was 9% (below the general population’s 15-20% rate), and preterm birth occurred in 15% of cases. While neonatal outcomes are largely positive (88% healthy), these statistics underscore the need for careful monitoring.

Analyzing the Evidence: Outcomes in Pregnant Women with SCS

While large clinical trials are lacking, a systematic review of 18 studies provides the most comprehensive evidence on SCS during pregnancy. The review included 25 patients across 32 pregnancies, offering valuable real-world insights.

The typical patient was around 33.5 years old at pregnancy, and crucially, 92% already had their SCS implanted. These women were managing debilitating conditions, primarily CRPS (72% of cases) and FBSS (24%). The data on their outcomes is encouraging.

Documented Maternal and Neonatal Outcomes

The results offer significant reassurance for women navigating this decision:

• Maternal Health: 100% of mothers remained healthy. The prenatal complication rate was 30%, with issues like hypertension or gestational diabetes, but the postnatal complication rate was only 6%.
• Pain Control: 84% of patients reported pain relief greater than 50%, demonstrating that SCS remains effective during pregnancy.
• Neonatal Health: 88% of newborns were healthy. The miscarriage rate was 9%, which is below the general population’s recognized rate of 15-20%. Full-term births occurred in 66% of cases, with preterm births at 15%.
• Delivery: 31% of women delivered vaginally, while 69% had cesarean sections, a rate likely influenced by the complexities of pain management during labor.

These positive findings, which can be contextualized with broader Patient Outcomes Research, suggest that with careful management, excellent outcomes are achievable.

Are Certain SCS Settings Safer for SCS during pregnancy?

As technology evolves, so do questions about optimal settings. Traditional SCS uses low-frequency stimulation, but newer high-frequency SCS (HF-SCS) at 10 kHz offers pain relief without the tingling sensation (paresthesia). One case report documented a woman with CRPS who successfully used 10 kHz HF-SCS through two pregnancies, delivering healthy babies each time. This suggests paresthesia-free stimulation might be a viable path forward.

Whether the lower energy per pulse of HF-SCS is safer remains a topic for further research. What is clear is that individualized programming adjustments are essential as the body changes during pregnancy. As highlighted in The Top 10 Breakthrough Studies in Spinal Cord Stimulation, innovation brings new possibilities but also requires continued study.

A Multidisciplinary Management Pathway for SCS During Pregnancy

Navigating SCS during pregnancy is not a solo journey; it requires a collaborative team approach. This is a core principle of Advanced Pain Management. Ideally, this team is assembled before conception for proactive planning, but it can be quickly formed if a pregnancy is unexpected.

The Role of the Multidisciplinary Team

Each member of your care team plays a vital role in ensuring a safe and healthy pregnancy:

• Obstetrician: Monitors maternal and fetal health and coordinates overall care.
• Pain Medicine Specialist: Manages the SCS device, adjusts programming, and helps weigh the risks and benefits of continued use.
• Anesthesiologist: Crucial for delivery planning, they assess the safety of anesthesia options like epidurals.
• Neonatologist: Monitors the baby’s development and is prepared for any special considerations at birth.
• Neurosurgeon: May be consulted for concerns about device integrity or lead migration.

This coordinated approach ensures all aspects of your health are managed cohesively.

Anesthetic and Delivery Considerations

Planning for labor and delivery with an SCS device requires careful thought. The primary concern is neuraxial anesthesia (epidurals and spinal blocks). Placing a needle near SCS leads carries a risk of lead damage and infection. Thoracic epidurals are generally contraindicated.

However, a lumbar epidural may be possible if the leads are located higher in the spine. An anesthesiologist must be consulted early to review imaging and determine a safe placement site, possibly using fluoroscopic guidance. Before any procedure, the SCS device must be interrogated and turned off. For surgeries, bipolar diathermy is preferred over monopolar to avoid electrical interference with the SCS system. The choice between vaginal delivery and C-section will depend on standard obstetric factors, with the SCS being one part of the overall decision-making process, as detailed in research on Management of SCS during labor and delivery.

Balancing Pain Control: SCS vs. Medication

The core dilemma is whether to keep the SCS on or turn it off and rely on medication. This decision is complex because many pain medications carry known risks. NSAIDs can cause serious problems in late pregnancy, and opioids are associated with neonatal abstinence syndrome. By providing effective, localized pain relief, SCS can be a powerful tool for Non-Pharmacological Pain Management, potentially reducing or eliminating the need for systemic drugs that could harm the fetus.

Furthermore, severe, uncontrolled chronic pain itself carries risks, including increased maternal stress and potential impacts on fetal development. For many women, the theoretical risks of continuing SCS may be less than the known harms of unmanaged pain and high-dose medication. This trade-off must be carefully weighed with your multidisciplinary team.

Frequently Asked Questions about SCS and Pregnancy

We understand that navigating SCS during pregnancy brings up many questions. Here, we address some of the most common concerns based on the best available evidence.

Should I turn my SCS device off if I become pregnant?

There is no simple yes-or-no answer. While manufacturers recommend deactivation due to a lack of comprehensive safety data, this decision must be individualized. Turning off your SCS could lead to a return of severe pain, which carries its own risks for you and your baby. It may also necessitate using pain medications with known risks. Case reports show that many women continue using their SCS with good outcomes, with 84% achieving significant pain relief and 100% of mothers remaining healthy.

The bottom line: Immediately consult your multidisciplinary care team. Your pain specialist and obstetrician will help you weigh the specific risks and benefits to create a personalized plan.

Can I have an epidural for labor if I have an SCS?

This is a significant concern and requires careful planning. An epidural is a relative contraindication due to the risk of damaging the SCS leads or causing an infection. Thoracic epidurals are considered an absolute contraindication.

However, a lumbar epidural for labor may be possible if your leads are located far from the insertion site. An anesthesiologist with obstetric and pain medicine experience should be consulted early in your pregnancy. They can use imaging like ultrasound or fluoroscopy to guide the needle safely. In some cases, general anesthesia for a C-section may be a safer alternative. Early planning with your team is key, as outlined in resources like Management of SCS during labor and delivery.

What are the known long-term effects on children born to mothers who used SCS?

This is a critical question with limited answers. Currently, there is very little data on the long-term outcomes for children exposed to SCS in utero. Existing reports, with follow-up periods averaging around 28 months, are encouraging: 88% of neonates are healthy at birth with no immediate complications linked to SCS.

However, the absence of long-term, large-scale research means that subtle or delayed effects cannot be completely ruled out. This is a critical gap in medical knowledge that future research must address. Participating in registry studies can help build the data needed to provide more definitive answers to future parents.

Conclusion: Navigating Pregnancy with an SCS

If you are managing chronic pain with a spinal cord stimulator and are pregnant or planning to be, you are navigating a complex but manageable journey. While the path has uncertainties, many women have successfully used SCS during pregnancy with positive outcomes for both themselves and their babies.

Informed, individualized decision-making is your most powerful tool. While manufacturers advise caution and theoretical risks exist, a growing body of evidence shows that SCS can be a viable option for maintaining quality of life and avoiding potentially harmful pain medications.

The evidence, though limited, is promising: case reviews show 100% of mothers remained healthy, 88% of newborns were healthy, and 84% of women achieved significant pain relief. These statistics represent real women who successfully managed their pain with the support of dedicated medical teams.

We cannot overstate the importance of a multidisciplinary team – an obstetrician, pain specialist, anesthesiologist, and neonatologist working together. This collaborative approach is the cornerstone of safe and effective management.

Future research is needed to provide more definitive answers about long-term outcomes. Until then, the best practice remains careful counseling, shared decision-making, and vigilant monitoring. Start the conversation with your care team early to develop a plan that feels right for you.

To stay informed on the latest developments, Learn more about Spinal Cord Stimulation and explore the educational resources here at Neuromodulation.